Metabolic Effects of Oral Phenelzine Treatment on High-Sucrose-Drinking Mice

Phenelzine has been suggested to have an antiobesity effect by inhibiting de novo lipogenesis, which led us to investigate the metabolic effects of oral chronic phenelzine treatment in high-sucrose-drinking mice. Sucrose-drinking mice presented higher body weight gain and adiposity versus controls....

Descripción completa

Detalles Bibliográficos
Autores: Carpene, Christian, Gomez-Zorita, Saioa, Chaplin, Alice, Mercader, Josep
Tipo de recurso: artículo
Fecha de publicación:2018
País:España
Institución:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositorio:Docusalut
Idioma:inglés
OAI Identifier:oai:docusalut.com:20.500.13003/9099
Acceso en línea:https://hdl.handle.net/20.500.13003/9099
Access Level:acceso abierto
Palabra clave:Monoamine Oxidase Inhibitors
Mice
Adipose Tissue, White
Sucrose
Lipogenesis
Weight Gain
Animals
Adiposity
Phenelzine
Fatty Acids, Nonesterified
Male
Obesity
Mice, Inbred C57BL
Administration, Oral
Oxidative Stress
Inhibidores de la Monoaminooxidasa
Tejido Adiposo Blanco
Fenelzina
Administración Oral
Masculino
Ácidos Grasos no Esterificados
Animales
Obesidad
Ratones Endogámicos C57BL
Aumento de Peso
Estrés Oxidativo
Ratones
Sacarosa
Lipogénesis
Adiposidad
phenelzine
obesity
adipocyte
lipogenesis
amine oxidases
hydrogen peroxide
hyperglycemia
oxidative stress
Descripción
Sumario:Phenelzine has been suggested to have an antiobesity effect by inhibiting de novo lipogenesis, which led us to investigate the metabolic effects of oral chronic phenelzine treatment in high-sucrose-drinking mice. Sucrose-drinking mice presented higher body weight gain and adiposity versus controls. Phenelzine addition did not decrease such parameters, even though fat pad lipid content and weights were not different from controls. In visceral adipocytes, phenelzine did not impair insulin-stimulated de novo lipogenesis and had no effect on lipolysis. However, phenelzine reduced the mRNA levels of glucose transporters 1 and 4 and phosphoenolpyruvate carboxykinase in inguinal white adipose tissue (iWAT), and altered circulating levels of free fatty acids (FFA) and glycerol. Interestingly, glycemia was restored in phenelzine-treated mice, which also had higher insulinaemia. Phenelzine-treated mice presented higher rectal temperature, which was associated to reduced mRNA levels of uncoupling protein 1 in brown adipose tissue. Furthermore, unlike sucrose-drinking mice, hepatic malondialdehyde levels were not altered. In conclusion, although de novo lipogenesis was not inhibited by phenelzine, the data suggest that the ability to re-esterify FFA is impaired in iWAT. Moreover, the effects on glucose homeostasis and oxidative stress suggest that phenelzine could alleviate obesity-related alterations and deserves further investigation in obesity models.